We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
The country’s strength lies not just in technology availability but in adoption behaviour
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
The investment case for health technology in India is frequently overstated in one direction and understated in another
.jpg "Why secure, empathetic home care defines the next era of healthcare delivery: Suhasini Deshmukh, Co-founder, MedRabbits")
Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Rising demands and advancements in eye care drive growth
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Subscribe To Our Newsletter & Stay Updated
